FHTX Q2 2020 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

FHTXFoghorn Therapeutics Inc.

$322M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$16M

Net Income

-$16M

EPS (Diluted)

$-0.71

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$15M

Stock-Based Comp.

$489,000

Balance Sheet

Total Assets

$94M

Total Liabilities

$76M

Stockholders' Equity

$18M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$16M	-$11M	-36.3%
Net Income	-$16M	-$11M	-38.3%